Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response

Journal of Medicinal Chemistry

Volumn 55, Issue 20, 2012, Pages 8903-8925

  Wong, Jason C ^a,d   Tang, Guozhi ^a   Wu, Xihan ^a   Liang, Chungen ^a   Zhang, Zhenshan ^a   Guo, Lei ^a   Peng, Zhenghong ^a   Zhang, Weixing ^a   Lin, Xianfeng ^a   Wang, Zhanguo ^a   Mei, Jianghua ^a   Chen, Junli ^a   Pan, Song ^a   Zhang, Nan ^a   Liu, Yongfu ^a   Zhou, Mingwei ^a   Feng, Lichun ^a   Zhao, Weili ^a   Li, Shijie ^a   Zhang, Chao ^a   Zhang, Meifang ^a   Rong, Yiping ^a   Jin, Tai Guang ^a   Zhang, Xiongwen ^a   Ren, Shuang ^a   Ji, Ying ^a   Zhao, Rong ^a   She, Jin ^a   Ren, Yi ^a   Xu, Chunping ^b   Chen, Dawei ^b   Cai, Jie ^b   Shan, Song ^c   Pan, Desi ^c   Ning, Zhiqiang ^c   Lu, Xianping ^c   Chen, Taiping ^b   He, Yun ^a   Chen, Li ^a   more..

^a Roche RandD Center China Ltd   (China)

^b Crown Bioscience Inc   (China)

^c Shenzhen Hi Tech Industrial Park   (China)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; RAC(TRANS 3,4)DISUBSTITUTED PYRROLIDINE DERIVATIVE; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE MODEL; DNA METHYLATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONFORMATION; DRUG EXPOSURE; DRUG POTENCY; DRUG SELECTIVITY; FEMALE; GENE EXPRESSION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PILOT STUDY; PROCESS OPTIMIZATION; PROMOTER REGION; SINGLE DRUG DOSE; TREATMENT RESPONSE; TUMOR XENOGRAFT;

EID: 84867790360     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3011838     Document Type: Article

References (40)

1. El-Seraq, H. B. Hepatocellular carcinoma N. Engl. J. Med. 2011, 365, 1118-1127
2. Bruix, J.; Llovet, J. M. Prognostic prediction and treatment strategy in hepatocellular carcinoma Hepatology 2002, 35, 519-524
3. Llovet, J. M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J. F.; de Oliveira, A. C.; Santoro, A.; Raoul, J. L.; Forner, A.; Schwartz, M.; Porta, C.; Zeuzem, S.; Bolondi, L.; Greten, T. F.; Galle, P. R.; Seitz, J. F.; Borbath, I.; Häussinger, D.; Giannaris, T.; Shan, M.; Moscovici, M.; Voliotis, D.; Bruix, J. Sorafenib in advanced hepatocellular carcinoma N. Engl. J. Med. 2008, 359, 378-390
4. Yang, X. J.; Seto, E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men Nat. Rev. Mol. Cell Biol. 2008, 9, 206-218
5. Grozinger, C. M.; Schreiber, S. L. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors Chem. Biol. 2002, 9, 3-16
6. Rikimaru, T.; Taketomi, A.; Yamashita, Y.; Shirabe, K.; Hamatsu, T.; Shimada, M.; Maehara, Y. Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma Oncology 2007, 72, 69-74
7. Yoo, Y. G.; Na, T. Y.; Seo, H. W.; Seong, J. K.; Park, C. K.; Shin, Y. K.; Lee, M. O. Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cells Oncogene 2008, 27, 3405-3413
8. Wang, H.; Guo, Y.; Fu, M.; Liang, X.; Zhang, X.; Wang, R.; Lin, C.; Qian, H. Antitumor activity of Chidamide in hepatocellular carcinoma cell lines Mol. Med. Rep. 2012, 5, 1503-1508
9. Ma, B. B.; Sung, F.; Tao, Q.; Poon, F. F.; Lui, V. W.; Yeo, W.; Chan, S. L.; Chan, A. T. The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines Invest. New Drugs 2010, 28, 107-114
10. Zhang, C; Li, H; Zhou, G; Zhang, Q; Zhang, T; Li, J; Zhang, J; Hou, J; Liew, C. T.; Yin, D. Transcriptional silencing of the TMS1/ASC tumour suppressor gene by an epigenetic mechanism in hepatocellular carcinoma cells J. Pathol. 2007, 212, 134-142
11. Wong, C. M.; Ng, Y. L.; Lee, J. M.; Wong, C. C.; Cheung, O. F.; Chan, C. Y.; Tung, E. K.; Ching, Y. P.; Ng, I. O. Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma Hepatology 2007, 45, 1129-1138
12. Baylin, S. B. DNA methylation and gene silencing in cancer Nat. Clin. Pract. Oncol. 2005, 2, S4-S11
13. Lu, Y. S.; Kashida, Y.; Kulp, S. K.; Wang, Y. C.; Wang, D.; Hung, J. H.; Tang, M.; Lin, Z. Z.; Chen, T. J.; Cheng, A. L.; Chen, C. S. Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma Hepatology 2007, 46, 1119-1130
14. See for example: clinical trials.gov identifiers NCT00823290, NCT00943449, and NCT00537121 at www.clinicaltrials.gov.
15. Miller, T. A.; Witter, D. J.; Belvedere, S. Histone deacetylase inhibitors J. Med. Chem. 2003, 46, 5097-5116
16. Wong, J. C.; Hong, R.; Schreiber, S. L. Structural biasing elements for in-cell histone deacetylase paralog selectivity J. Am. Chem. Soc. 2003, 125, 5586-5587
17. Ning, Z. Q.; Li, Z. B.; Newman, M. J.; Shan, S.; Wang, X. H.; Pan, D. S.; Zhang, J.; Dong, M.; Du, X.; Lu, X. P. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity Cancer Chemother. Pharmacol. 2012, 69, 901-909
18. Yap, T. A.; Sandhu, S. K; Workman, P.; de Bono, J. S. Envisioning the future of early anticancer drug development Nat. Rev. Cancer 2010, 10, 514-523
19. Venugopal, B.; Evans, T. R. Developing histone deacetylase inhibitors as anti-cancer therapeutics Curr. Med. Chem. 2011, 18, 1658-1671
20. Khan, O.; Fotheringham, S.; Wood, V.; Stimson, L.; Zhang, C.; Pezzella, F.; Duvic, M.; Kerr, D. J.; La Thangue, N. B. HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 6532-6537
21. Miyanaga, A.; Gemma, A.; Noro, R.; Kataoka, K.; Matsuda, K.; Nara, M.; Okano, T.; Seike, M.; Yoshimura, A.; Kawakami, A.; Uesaka, H.; Nakae, H.; Kudoh, S. Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model Mol. Cancer Ther. 2008, 7, 1923-1930
22. Dejligbjerg, M.; Grauslund, M.; Christensen, I. J.; Tjrnelund, J.; Buhl Jensen, P.; Sehested, M. Identification of predictive biomarkers for the histone deacetylase inhibitor belinostat in a panel of human cancer cell lines Cancer Biomark. 2008, 4, 101-109
23. Fantin, V. R.; Loboda, A.; Paweletz, C. P.; Hendrickson, R. C.; Pierce, J. W.; Roth, J. A.; Li, L.; Gooden, F.; Korenchuk, S.; Hou, X. S.; Harrington, E. A.; Randolph, S.; Reilly, J. F.; Ware, C. M.; Kadin, M. E.; Frankel, S. R.; Richon, V. M. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma Cancer Res. 2008, 68, 3785-3794
24. For a general review on the subject of HDACi and biomarkers, refer to: Stimson, L.; La Thangue, N. B. Biomarkers for predicting clinical responses to HDAC inhibitors Cancer Lett. 2009, 280, 177-183
25. Wong, J. C.; Guo, L.; Peng, Z. H.; Zhang, W. X.; Zhang, N.; Lai, W.; Zhang, Z. S.; Song, S.; Pan, D. S.; Ning, Z. Q.; Lu, X. P.; Zhang, X. W.; Zhang, C.; Li, J.; Xie, C. M.; He, Y.; Chen, L. Application of p21 and klf2 reporter gene assays to identify selective histone deacetylase inhibitors for cancer therapy Bioorg. Med. Chem. Lett. 2011, 21, 110-116
26. Zhao, H. Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective Drug Discovery Today 2007, 12, 149-155
27. Joucla, M.; Mortier, J. 2,5-Unsubstituted pyrrolidines from formaldehyde and amino acids through in situ azomethine-ylide 1,3-dipolar cycloaddition to alkenes J. Chem. Soc., Chem. Commun. 1985, 22, 1566-1567
28. Evans, D. A.; Mito, S.; Seidel, D. Scope and mechanism of enantioselective Michael additions of 1,3-dicarbonyl compounds to nitroalkenes catalyzed by nickel(II)-diamine complexes J. Am. Chem. Soc. 2007, 129, 11583-11592
29. Yan, L.; Budhu, R.; Huo, P.; Lynch, C. L.; Hale, J. J.; Mills, S. G.; Hajdu, R.; Keohane, C. A.; Rosenbach, M. J.; Milligan, J. A.; Shei, G. J.; Chrebet, G.; Bergstrom, J.; Card, D.; Mandala, S. M. 2-Aryl(pyrrolidin-4-yl) acetic acids are potent agonists of sphingosine-1-phosphate (S1P) receptors Bioorg. Med. Chem. Lett. 2006, 16, 3564-3568
30. For more information about HuPrime tumor-derived xenograft models versus traditional cell line-derived xenograft models, see the website of Crown Biosciences (Santa Clara, CA) at www.crownbio.com.
31. For more information, see www.ingenuity.com (Ingenuity Systems, Redwood City, CA).
32. See PubMeth website: http://methycancer.psych.ac.cn/MethyCancer.do.
33. Cameron, E. E.; Bachman, K. E.; Myöhänen, S.; Herman, J. G.; Baylin, S. B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer Nat. Genet. 1999, 21, 103-107
34. Morris, M. R.; Gentle, D.; Abdulrahman, M.; Maina, E. N.; Gupta, K.; Banks, R. E.; Wiesener, M. S.; Kishida, T.; Yao, M.; Teh, B.; Latif, F.; Maher, E. R. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma Cancer Res. 2005, 65, 4598-4606
35. MacroModel, formerly known as BatchMin, is a general-purpose molecular mechanics program available from Schrödinger, L.L.C., New York. MacroModel was developed in the laboratories of Prof. Clark Still (Columbia University).
36. Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. Extra precision Glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes J. Med. Chem. 2006, 49, 6177-6196
37. Testino, S. A. J.; Patonay, G. High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry J. Pharm. Biomed. Anal. 2003, 30, 1459-1467
38. Walsky, R. L.; Obach, R. S. Validated assays for human cytochrome P450 activities Drug Metab. Dispos. 2004, 32, 647-660
39. Weaver, R.; Graham, K. S.; Beattie, I. G.; Riley, R. J. Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation Drug Metab. Dispos. 2003, 31, 955-966
40. Liang, G.; Guthrie, H. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation J. Pharmacol. Toxicol. Methods 2005, 52, 123-135